LONG MINI-FUTURE - GENMAB | Real-time Boerse Frankfurt Warrants 09:20:14 27/06/2024 BST | ||
| 2.95 EUR | +4.61% |
|
| Current month | -41.49% | ||
| 1 month | -43.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 2.95 | +4.61% |
| 26/06/24 | 2.82 | +2.92% |
| 25/06/24 | 2.74 | -2.14% |
| 24/06/24 | 2.8 | -3.11% |
| 20/06/24 | 2.89 | +16.53% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 09:20 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP16DR |
| ISIN | DE000VP16DR3 |
| Date issued | 02/04/2020 |
| Strike | 1,578 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.78 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.4 € |
|---|---|
| Lowest since issue | 0.73 € |
| Spread | 0.02 € |
| Spread % | 0.67% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,791
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.58%
- Stock Market
- Certificates
- Certificat
